-+ 0.00%
-+ 0.00%
-+ 0.00%

Evotec 9M 2026 operating loss more than doubles to EUR 254.78 million

PUBT·11/05/2026 06:30:36
Listen to the news
Evotec 9M 2026 operating loss more than doubles to EUR 254.78 million
  • Evotec’s net loss widened 65% year-over-year to EUR 195.3 million in the first nine months of 2026, partly due to higher restructuring costs.
  • Revenue fell 13% to EUR 465 million, with lower revenue recognition across all Discovery & Preclinical Development businesses.
  • Operating cash outflow more than doubled to EUR 155 million, primarily reflecting operating performance and related working-capital changes.
  • The Horizon transformation ran slightly ahead of schedule, supporting plans to realize some targeted annual savings earlier.
  • Full-year 2026 revenue guidance remained unchanged at EUR 570 million to EUR 610 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evotec SE published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.